Financial Contrast: Nektar Therapeutics (NASDAQ:NKTR) and Cronos Group (NASDAQ:CRON)

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Cronos Group (NASDAQ:CRON – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Nektar Therapeutics and Cronos Group’s net margins, return on equity and return on assets.

Volatility & Risk

Nektar Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Nektar Therapeutics and Cronos Group, as reported by MarketBeat.

Nektar Therapeutics currently has a consensus target price of $149.63, suggesting a potential upside of 141.21%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 15.75%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Cronos Group.

Valuation & Earnings

This table compares Nektar Therapeutics and Cronos Group”s top-line revenue, earnings per share (EPS) and valuation.

Cronos Group has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cronos Group beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

About Cronos Group

(Get Free Report)

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.